
Organovo Holdings ONVO
Quartalsbericht 2025-Q4
hinzugefügt 11.02.2026
Organovo Holdings Langfristige Verbindlichkeiten 2011-2026 | ONVO
Langfristige Verbindlichkeiten Jährlich Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 588 K | 583 K | 807 K | 905 K | 32 K | 9 K | 30 K | 17 K | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 905 K | 9 K | 371 K |
Langfristige Verbindlichkeiten anderer Aktien in der Diagnostik & Forschung
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M | ||
|
Bioventus
BVS
|
238 M | $ 9.26 | 1.09 % | $ 617 M | ||
|
Biodesix
BDSX
|
62.1 M | $ 14.6 | -3.63 % | $ 1.89 B | ||
|
DarioHealth Corp.
DRIO
|
32.8 M | $ 8.45 | 9.74 % | $ 33.7 M | ||
|
DexCom
DXCM
|
1.15 B | $ 66.09 | -1.12 % | $ 25.8 B | ||
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
ICON Public Limited Company
ICLR
|
461 M | $ 103.08 | 3.09 % | $ 8.5 B | ||
|
IDEXX Laboratories
IDXX
|
597 M | $ 573.29 | -0.42 % | $ 46.1 B | ||
|
Illumina
ILMN
|
2.04 B | $ 124.4 | -1.43 % | $ 19.8 B | ||
|
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
3.56 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 466.6 | -0.04 % | $ 13.5 B | ||
|
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
559 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | ||
|
Myriad Genetics
MYGN
|
107 M | $ 4.62 | -1.28 % | $ 428 M | ||
|
National Research Corporation
NRC
|
39.6 M | $ 17.52 | 1.98 % | $ 392 M | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | ||
|
Natera
NTRA
|
124 M | $ 196.15 | -0.62 % | $ 19.3 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | ||
|
Charles River Laboratories International
CRL
|
2.35 B | $ 165.13 | -0.46 % | $ 8.18 B | ||
|
OpGen
OPGN
|
21.2 M | - | -16.95 % | $ 1.54 M | ||
|
OPKO Health
OPK
|
642 M | $ 1.17 | -1.68 % | $ 812 M | ||
|
Pacific Biosciences of California
PACB
|
43.9 M | $ 1.35 | -2.88 % | $ 405 M | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
ENDRA Life Sciences
NDRA
|
1.29 M | $ 4.59 | 22.4 % | $ 2.46 M | ||
|
PerkinElmer
PKI
|
2.96 B | - | -0.91 % | $ 14.7 B | ||
|
Invitae Corporation
NVTA
|
320 M | - | - | $ 21.2 M | ||
|
Personalis
PSNL
|
639 K | $ 7.32 | -4.94 % | $ 434 M | ||
|
Interpace Biosciences
IDXG
|
10 M | $ 1.73 | 2.37 % | $ 7.59 M | ||
|
RadNet
RDNT
|
1.09 B | $ 59.41 | -2.06 % | $ 4.47 B | ||
|
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | ||
|
QIAGEN N.V.
QGEN
|
1.58 B | - | - | $ 10.6 B | ||
|
Celcuity
CELC
|
69.2 K | $ 114.81 | 4.16 % | $ 4.53 B | ||
|
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | ||
|
Senseonics Holdings
SENS
|
163 M | $ 6.56 | -2.96 % | $ 274 M | ||
|
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 268.38 | 0.89 % | $ 22.3 B | ||
|
NeoGenomics
NEO
|
435 M | $ 7.76 | -0.13 % | $ 994 M | ||
|
Soleno Therapeutics
SLNO
|
10.8 M | $ 31.83 | -0.03 % | $ 1.62 B | ||
|
Psychemedics Corporation
PMD
|
4.88 M | - | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
1.9 M | $ 27.2 | -0.15 % | $ 35.3 M |